Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 1/20 | 0.51 |
| ▸ | FEN1 | P39748 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 14/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15326968 | 0.98 | CREBBP (0.50) | CREBBPFEN1MAOBLMNAMAPT | |
| SCHEMBL5901517 | 0.86 | CREBBP (0.52) | CREBBPFEN1LMNAMAPTL3MBTL1 | |
| SCHEMBL9977750 | 0.84 | FEN1 (0.50) | CREBBPFEN1MAPTL3MBTL1 | |
| Hydrochloric Acid SCHEMBL15327063 | 0.82 | FEN1 (0.49) | CREBBPFEN1LMNAMAPTL3MBTL1 | |
| SCHEMBL103796 | 0.82 | CREBBP (0.46) | CREBBPFEN1LMNAMAPTL3MBTL1 | |
| SCHEMBL4653938 | 0.81 | L3MBTL1 (0.65) | CREBBPFEN1L3MBTL1KCNH2GRIN2B | |
| SCHEMBL28034436 | 0.79 | SIGMAR1 (0.49) | CREBBP | |
| SCHEMBL15604664 | 0.78 | CREBBP (0.46) | CREBBPFEN1MAOBLMNAMAPT | |
| SCHEMBL414600 | 0.78 | SMN1; SMN2 (0.52) | CREBBP | |
| Hydrochloric Acid SCHEMBL16648689 | 0.77 | CREBBP (0.45) | CREBBPFEN1LMNAMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130281465-A1 | PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-24 | — | — | US | disclosed |
| US-20130281465-A1 | PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-24 | — | — | US | disclosed |
| WO-2012081692-A1 | PYRAZOLE DERIVATIVE | 大正製薬株式会社 (JP) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281465-A1 | PYRAZOLE DERIVATIVE | HCRTR1, HCRTR2, NPY4R | CREBBP 416/4885FEN1 4849/4885MAOB 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.